US92337R1014

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on…

1 week ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the…

4 weeks ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025 16:05 ET  | Source: Vera Therapeutics BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc.…

2 months ago